FDA Warning Asks Novartis for Global Manufacturing Assessment

The FDA is asking Novartis for a comprehensive, global manufacturing assessment after it sharply scored the company for multiple repeated quality failures at plants operated by its Sandoz subsidiary.
Washington Drug Letter